ANGIOGENICALLY EFFECTIVE UNIT DOSE OF FGF-2 AND METHOD OF USE

摘要

PROBLEM TO BE SOLVED: To provide a pharmaceutical composition for inducing angiogenesis in human heart and a method for including the same. SOLUTION: A unit dose composition of a pharmaceutically acceptable carrier includes 0.2-48μg/kg of a FGF-2 with SEQ ID NO 2 or an active fragment for angiogenesis of the same or an angiogenically active mutein. A method for treatment of a human patient with a coronary arterial disease (including a step of administering an effective dose for a stable angiogenesis in one or more coronary artery/arteries or one peripheral vein with a recombinant FGF-2 or an angiogenically active fragment of the same or the angiogenically active mutein) is provided. One unit dose composition provides the angiogenic effect lasting for six months before requiring re-treatment in a human CAD patient; and an optimal safe administration method for a patient (all of a liquid, heparin and/or an infusion rate fulfill the role). COPYRIGHT: (C)2010,JPO&INPIT